Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy (Q28087741)

language of work or name

1 reference

May 2015

1 reference

1 reference

137

1 reference

PubMed

issue

2

1 reference

PubMed

page(s)

343-50

1 reference

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Identification of the breast cancer susceptibility gene BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Mutations in BRIP1 confer high risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Germline mutations in RAD51D confer susceptibility to ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Regulation and mechanisms of mammalian double-strand break repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Mechanism of homologous recombination: mediators and helicases take on regulatory functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Homologous recombination and its regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Hallmarks of 'BRCAness' in sporadic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Improved survival in women with BRCA-associated ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.017